Literature DB >> 36169327

In Vitro Activity of Tebipenem against Various Resistant Subsets of Escherichia coli Causing Urinary Tract Infections in the United States (2018 to 2020).

Rodrigo E Mendes1, Cory Hubler1, J H Kimbrough1, Valerie Kantro1, Ian Critchley2, Nicole Cotroneo2, Mariana Castanheira1.   

Abstract

This study investigated the activity of an oral carbapenem, tebipenem, against various molecularly characterized subsets of Escherichia coli. A total of 15.0% of E. coli isolates (360/2,035 isolates) met the MIC criteria for screening for β-lactamases. Most of those isolates (74.7% [269/360 isolates]) carried blaCTX-M. The CTX-M distribution varied (50% to 86%) among Census Regions, as did that of plasmid AmpC genes (up to 41% among E. coli isolates from the New England Region). Tebipenem and intravenous carbapenems showed uniform activity against various E. coli subsets.

Entities:  

Keywords:  CTX-M; ESBL; ST131; carbapenems; oral; resistance; surveillance

Mesh：

Substances：

Year:  2022        PMID： 36169327      PMCID： PMC9578410          DOI： 10.1128/aac.01214-22

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.938


  13 in total

1.  Antimicrobial-resistant pathogens associated with adult healthcare-associated infections: Summary of data reported to the National Healthcare Safety Network, 2015-2017.

Authors:  Lindsey M Weiner-Lastinger; Sheila Abner; Jonathan R Edwards; Alexander J Kallen; Maria Karlsson; Shelley S Magill; Daniel Pollock; Isaac See; Minn M Soe; Maroya S Walters; Margaret A Dudeck
Journal:  Infect Control Hosp Epidemiol       Date:  2019-11-26       Impact factor: 3.254

2.  Piperacillin-Tazobactam Versus Carbapenems for the Treatment of Nonbacteremic Urinary Tract Infections due to Extended-Spectrum Beta-Lactamase-Producing Enterobacteriaceae.

Authors:  Jordan Brooke Tullos; Laura Leigh Stoudenmire; Jonathon David Pouliot
Journal:  Hosp Pharm       Date:  2018-12-07

Review 3.  International clinical practice guidelines for the treatment of acute uncomplicated cystitis and pyelonephritis in women: A 2010 update by the Infectious Diseases Society of America and the European Society for Microbiology and Infectious Diseases.

Authors:  Kalpana Gupta; Thomas M Hooton; Kurt G Naber; Björn Wullt; Richard Colgan; Loren G Miller; Gregory J Moran; Lindsay E Nicolle; Raul Raz; Anthony J Schaeffer; David E Soper
Journal:  Clin Infect Dis       Date:  2011-03-01       Impact factor: 9.079

Review 4.  A new clone sweeps clean: the enigmatic emergence of Escherichia coli sequence type 131.

Authors:  Ritu Banerjee; James R Johnson
Journal:  Antimicrob Agents Chemother       Date:  2014-05-27       Impact factor: 5.191

5.  Clonal composition and community clustering of drug-susceptible and -resistant Escherichia coli isolates from bloodstream infections.

Authors:  Sheila Adams-Sapper; Binh An Diep; Francoise Perdreau-Remington; Lee W Riley
Journal:  Antimicrob Agents Chemother       Date:  2012-11-12       Impact factor: 5.191

Review 6.  Extended-Spectrum β-Lactamase-Producing Enterobacteriaceae: Update on Molecular Epidemiology and Treatment Options.

Authors:  Gisele Peirano; Johann D D Pitout
Journal:  Drugs       Date:  2019-09       Impact factor: 9.546

7.  Oral Tebipenem Pivoxil Hydrobromide in Complicated Urinary Tract Infection.

Authors:  Paul B Eckburg; Lori Muir; Ian A Critchley; Susannah Walpole; Hanna Kwak; Anne-Marie Phelan; Gary Moore; Akash Jain; Tim Keutzer; Aaron Dane; David Melnick; Angela K Talley
Journal:  N Engl J Med       Date:  2022-04-07       Impact factor: 176.079

8.  Randomized controlled trial of piperacillin-tazobactam, cefepime and ertapenem for the treatment of urinary tract infection caused by extended-spectrum beta-lactamase-producing Escherichia coli.

Authors:  Yu Bin Seo; Jacob Lee; Young Keun Kim; Seung Soon Lee; Jeong-A Lee; Hyo Youl Kim; Young Uh; Han-Sung Kim; Wonkeun Song
Journal:  BMC Infect Dis       Date:  2017-06-07       Impact factor: 3.090

9.  Application of Next-Generation Sequencing for Characterization of Surveillance and Clinical Trial Isolates: Analysis of the Distribution of β-lactamase Resistance Genes and Lineage Background in the United States.

Authors:  Rodrigo E Mendes; Ronald N Jones; Leah N Woosley; Vincent Cattoir; Mariana Castanheira
Journal:  Open Forum Infect Dis       Date:  2019-03-15       Impact factor: 3.835

Review 10.  Antimicrobial Stewardship and Urinary Tract Infections.

Authors:  Lilian M Abbo; Thomas M Hooton
Journal:  Antibiotics (Basel)       Date:  2014-05-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.